<DOC>
	<DOC>NCT01109485</DOC>
	<brief_summary>The objective of this study is to further evaluate the safety of Olopatadine Ophthalmic Solution 0.1% in Japanese children with allergic conjunctivitis.</brief_summary>
	<brief_title>Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patients whose parents or guardians can issue informed consent Patients aged over 7 and less than 16 at the baseline Patients confirmed to show type I allergy Patients with allergic conjunctivitis Patients having subjective symptoms at the baseline (itching sensation, foreign body sensation, eye pain, etc.) Patients having ocular itching sensation and injection caused by disease other than allergic conjunctivitis Patients having retinal detachment, diabetic retinopathy or progressive retinal disease Patients with a history of ocular infection, corneal herpes or relapsing corneal erosion of sudden onset or secondary to corneal injury Patients having received continuous treatment with corticosteroid within 3 months Patients having received immunotherapy Patients requiring continuous treatment of corticosteroid, immunosuppressors, nonsteroidal antiinflammatory agents, vasoconstrictors, antihistamines, antiallergy agents, herbal preparations indicated for "conjunctivitis" or any ophthalmic solution other than the test product Patients having undergone ocular laser therapy within 3 months Unilaterally blind patients (best corrected visual acuity: below 0.01) Patients with a history of allergy or hypersensitivity to olopatadine hydrochloride Patients necessitating the use of contact lens during the study period Other patients judged by the attending physician as inappropriate for study</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Allergic conjunctivitis</keyword>
</DOC>